Literature DB >> 10906203

Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection.

J Podlech1, R Holtappels, M F Pahl-Seibert, H P Steffens, M J Reddehase.   

Abstract

Interstitial pneumonia (IP) is a severe organ manifestation of cytomegalovirus (CMV) disease in the immunocompromised host, in particular in recipients of bone marrow transplantation (BMT). Diagnostic criteria for the definition of CMV-IP include clinical evidence of pneumonia together with CMV detected in bronchoalveolar lavage or lung biopsy. We have used the model of syngeneic BMT and simultaneous infection of BALB/c mice with murine CMV for studying the pathogenesis of CMV-IP by controlled longitudinal analysis. A disseminated cytopathic infection of the lungs with fatal outcome was observed only when reconstituting CD8 T cells were depleted. Neither CD8 nor CD4 T cells mediated an immunopathogenesis of acute CMV-IP. By contrast, after efficient hematolymphopoietic reconstitution, viral replication in the lungs was moderate and focal. The histopathological picture was dominated by preferential infiltration of CD8 T cells confining viral replication to inflammatory foci. Notably, after clearance of acute infection, CD62L(lo) and CD62L(hi) subsets of CD44(+) memory CD8 T cells were found to persist in lung tissue. One can thus operationally distinguish an early CMV-positive IP (phase 1) and a late CMV-negative IP (phase 2). According to the definition, phase 2 histopathology would not be diagnosed as a CMV-IP and could instead be misinterpreted as a CMV-induced immunopathology. We document here that phase 1 as well as phase 2 pulmonary CD8 T cells are capable of exerting effector functions and are effectual in protecting against productive infection. We propose that antiviral "stand-by" memory-effector T cells persist in the lungs to prevent virus recurrence from latency.

Entities:  

Mesh:

Year:  2000        PMID: 10906203      PMCID: PMC112270          DOI: 10.1128/jvi.74.16.7496-7507.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  The immunogenicity of human and murine cytomegaloviruses

Authors: 
Journal:  Curr Opin Immunol       Date:  2000-12       Impact factor: 7.486

Review 2.  Cytomegalovirus pneumonia.

Authors:  N Salomon; D C Perlman
Journal:  Semin Respir Infect       Date:  1999-12

3.  Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.

Authors:  M Alterio de Goss; R Holtappels; H P Steffens; J Podlech; P Angele; L Dreher; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Evidence against a key role for transforming growth factor-beta1 in cytomegalovirus-induced bone marrow aplasia.

Authors:  M Dobonici; J Podlech; H P Steffens; S Maiberger; M J Reddehase
Journal:  J Gen Virol       Date:  1998-04       Impact factor: 3.891

6.  A cell-surface molecule involved in organ-specific homing of lymphocytes.

Authors:  W M Gallatin; I L Weissman; E C Butcher
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

7.  Risk factors for cytomegalovirus infection after human marrow transplantation.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

8.  In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.

Authors:  B Hertenstein; W Hampl; D Bunjes; M Wiesneth; C Duncker; U Koszinowski; H Heimpel; R Arnold; T Mertens
Journal:  Bone Marrow Transplant       Date:  1995-03       Impact factor: 5.483

9.  Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation.

Authors:  J R Wingard; D Y Chen; W H Burns; D J Fuller; H G Braine; A M Yeager; H Kaiser; P J Burke; M L Graham; G W Santos
Journal:  Blood       Date:  1988-05       Impact factor: 22.113

10.  L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites.

Authors:  T F Tedder; D A Steeber; P Pizcueta
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  67 in total

1.  Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs.

Authors:  N K Grzimek; D Dreis; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

Authors:  R Holtappels; M F Pahl-Seibert; D Thomas; M J Reddehase
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Transient CD8-memory contraction: a potential contributor to latent cytomegalovirus reactivation.

Authors:  Jonathan Campbell; Joanne Trgovcich; Michelle Kincaid; Peter D Zimmerman; Paul Klenerman; Stuart Sims; Charles H Cook
Journal:  J Leukoc Biol       Date:  2012-06-22       Impact factor: 4.962

Review 6.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

7.  Age-related dysregulation of CD8+ T cell memory specific for a persistent virus is independent of viral replication.

Authors:  Anna Lang; James D Brien; Ilhem Messaoudi; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 8.  Mast cells: innate attractors recruiting protective CD8 T cells to sites of cytomegalovirus infection.

Authors:  Jürgen Podlech; Stefan Ebert; Marc Becker; Matthias J Reddehase; Michael Stassen; Niels A W Lemmermann
Journal:  Med Microbiol Immunol       Date:  2015-02-04       Impact factor: 3.402

9.  Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens.

Authors:  Anna Lang; James D Brien; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.

Authors:  Meghan R Forster; Joanne Trgovcich; Peter Zimmerman; Alexander Chang; Cortland Miller; Paul Klenerman; Charles H Cook
Journal:  Antiviral Res       Date:  2009-12-11       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.